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Aim. Generation of polyclonal antibodies specifi c to the ribosomal protein S6 kinase isoform – p85S6K1 
and directed to the N-terminal (1-23 aa) extension of p85S6K1. Methods. Animal immunization with 
synthetic (1–23 aa) peptide, ELISA, western blot, immunoprecipitation, immunofl uorescent analysis. 
Results. Polyclonal antibodies have been generated, which specifi cally recognize only p85 but not p70 
isoform of S6K1 in western blot, immunoprecipitation and immunofl uorescence analysis. Conclusions. 
The obtained antibodies can be recommended for studies on the p85S6K1 and other S6K1 isoforms pos-
sessing the N-terminal extension – the identifi cation of binding protein partners, analysis of subcellular 
localization under different physiological conditions, elucidation of the signal transduction pathways 
involving different S6K1 isoforms.
K e y w o r d s: Ribosomal protein S6 kinase 1 (S6K1), S6K1 isoforms, p70 S6K1, p85 S6K1, polyclonal 
antibodies.
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Introduction
The ribosomal protein S6 kinase1 (S6K1) is a serine/
threonine kinase activated in response to the growth 
factors, cytokines and nutrients. S6K1 has been 
linked to the diverse cellular processes, including 
protein synthesis, mRNA processing, glucose home-
ostasis, cell growth and survival. Studies on model 
organisms have highlighted a role that the S6K ac-
tivity plays in a number of pathologies, including 
obesity, diabetes, ageing and cancer [reviewed in 1]. 
S6K1 belongs to the PI3K/Akt/mTOR pathway that 
is one of the major signalling pathways hyperacti-
vated in many cancers causing the uncontrolled pro-
liferation, increased survival, motility, and invasive-
ness of the cancer cells [2–4].
The major known substrate of S6K1 is the 40 S 
ribosomal subunit protein S6 [5, 6], however about 
twenty additional S6K1 substrates have already been 
identifi ed [reviewed in 1]. 
Two isoforms of the enzyme, denoted as p70S6K1 
and p85S6K1, are generated from a single gene by 
the use of alternative mRNA translational start sites, 
and differ only by the 23 aa N-terminal extension 
unique for the p85 isoform [7]. The N-terminal ex-
tension of p85S6K1 bears a putative nuclear locali-
zation signal that targets this isoform to the nucleus 
[7]. This was confi rmed by immunofl uorescence 
analysis of the rat embryo fi broblasts (REF-52) with 
p85S6K1 specifi c antibodies directed to the 8–23 aa 
sequence within the 23aa N-terminal extension of 
p85S6K1 [8]. The same authors demonstrated that 
microinjection of the affi nity purifi ed anti-p85S6K1 
IgG into the nucleus, but not the cytoplasm, blocked 
the serum-induced initiation of DNA synthesis and 
the G1/S transition.
295
Generation and characterization of polyclonal antibodies specifi c
Despite the absence of a classical NLS, p70S6K1 
can be also localized in the nucleus due to the shut-
tling from the cytoplasm to the nucleus upon the 
growth factor stimulation [9]. Moreover, phosphor-
ylation of S17 by CK2 greatly enhances the nuclear 
export of p70S6K1 [10].
A number of nuclear substrates of S6K are identi-
fi ed so far, such as transcription factor CREM, 
MDM2 ubiquitine ligase, splicing complex protein 
SKAR, etc. [reviewed in 1] but it is not clear which 
of S6K1 isoforms is responsible for the phosphor-
ylation and what are the precise functions of p70S6K1 
and p85S6K1 in the nucleus. 
In addition to the full-length forms of S6K1, 
novel S6K1 shorter splice variants in mice and hu-
man that can also possess the N-terminal NLS 
have been reported [11, 12]. Unlike the full-length 
S6K1, the identifi ed splice isoforms, having no 
catalytical activity due to the truncation in the 
catalytical domain, possess the cell transforming 
activity. 
The immunohistochemical analysis of S6K1 in 
different human breast, endometrial and thyroid tu-
mours, revealed an increased level of S6K1 and al-
terations in the S6K1 subcellular localization [13–
15]. In 25 % of breast adenocarcinoma cases and in 
8 % of endometrial tumours the nuclear localization 
of S6K1 has been detected [16–18]. However, it 
was not clear which of two S6K1 isoforms was de-
tected in the nucleus since the antibodies used were 
specifi c to the C-terminal sequence common for the 
p70S6K1 and p85S6K1 isoforms.
The aim of this work was to generate the poly-
clonal antibodies specifi c to the N-terminal (1-23 
aa) extension unique for p85S6K1 that could dis-
tinguish the p70 and p85 isoforms of S6K1. This 
type of antibodies may be used for the analysis of 
the subcellular localization of the S6K1 isoforms in 
cells under different physiological conditions as 
well as in tumour cells of different types. In addi-
tion they may be very useful for the analysis of 
S6K1 dependent cell signalling in context of differ-
ent functions of the p70 and p85 isoforms of S6K1 
and the recently discovered oncogenic S6K1 splice 
isoforms [11, 12]. 
Materials and Methods
Antibodies. Mouse monoclonal (C3/10) and rabbit 
polyclonal (anti-S6K1/C) antibodies specifi c to the 
C-terminal (454–525 aa) sequence of p85S6K1 have 
been generated as described previously [19, 20]. For 
the generation of mouse polyclonal antibodies (a-
S6K1/1–77) specifi c to the N-terminus of S6K1 as 
an antigen we used recombinant peptide correspond-
ing to the 1–77 aa sequence of p85S6K1 (unpublished 
data). Rabbit monoclonal antibodies (clone 16) spe-
cifi c to the N-terminal sequence (1–122 aa) of 
p70S6K1 were from BD Bioscience (USA). 
Generation of polyclonal antibodies specifi c to 
the N-terminal extension of p85S6K1. As an antigen 
for immunization we used a «spider» construct. For 
this purpose, the synthetic peptide CR50 (MRRRRRR 
DGFYPAPDFRHREAED) that corresponded to the 
N-terminal (1–23 aa) extension of p85S6K1 was im-
mobilized on the surface of sepharose beads by 
chemical crosslinking (Provided by Alta Bioschience, 
Birmingham, UK). 
For immunization we used one rabbit (New Zea-
land White Rabbits, weight – 3 kg, age – 6 months). 
The antigen/adjuvant mixture was inoculated into ten 
sites subcutaneously along the back. We used 0.1 ml 
of the mixture per site. 0.5 ml of «spider» suspension 
(equivalent to CR50 peptide concentration of 1 mg/
ml) was mixed with 0.5 ml of Complete Freund’s 
Adjuvant (for initial inoculation) and 0.5 ml of In-
complete Freund’s Adjuvent (for the following injec-
tions). The immunizations were performed every four 
weeks. When the titer of antiserum reached 10-4 the 
blood was collected for the anti-serum preparation 
and further purifi cation of the antibodies. 
Purifi cation of the anti-p85S6K1 antibodies was 
performed by affi nity chromatography. The CR50 
peptide was immobilised on NHS-activated Sep ha-
rose (Amersham) according to the recommendation 
of manufacturer. Then 5 ml of anti-sera diluted with 
PBS (1:1) were incubated overnight at +4 C on the 
wheel in 10ml column with 1ml of the affi nity ma-
trix priory washed in PBS. After incubation the af-
fi nity matrix was washed fi ve times with 10 ml of 
PBS. Elution of the anti-CR50 antibodies was per-
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formed by 100mM Glycine (pH 2.5) with immediate 
neutralisation of the antibody eluates by 1M Tris (pH 
8.8). After dialysis in PBS the purifi ed antibodies were 
aliquoted and stored at – 70 C with 50 % glycerol. 
Western blot analysis – The cell lysates were 
prepared using a lysis buffer containing 20 mM 
Tris-HCl, pH 7.5, 150 mM NaCl, 1 % Triton X-100, 
50 mM NaF, 5 mM EDTA, and a mixture of pro-
tease inhibitors (Roche Molecular Diagnostics, 
France). The cell lysates (25 μg) were separated by 
SDS-PAGE and transferred onto Immobilon-P 
membrane (Millipore, USA). The membrane was 
blocked with 5 % skim milk in TBST (50 mM Tris-
HCl, pH 7.4, 150 mM NaCl and 0.05 % Tween-20) 
for 1 h at RT, and then incubated with correspond-
ing antibodies dilutions for 1 h at RT. After wash-
ing with TBST, membrane was incubated with the 
HRP-conjugated goat anti-mouse IgG in 1:6000 di-
lution for 1 h at RT. (Jackson ImmunoResearch, 
USA). Finally, the membrane was developed using 
an ECL kit (GE Healthcare, USA) and then exposed 
to Agfa X-ray fi lm.
Immunoprecipitation – 1μg of mAbs purifi ed from 
ascites or 1μg of affi nity purifi ed polyclonal antibod-
ies was incubated with 25 μl of 50 % protein G-Se-
pharose and 500 μg of cell extract in a total volume 
of 500 μl of lysis buffer and rotated at + 4°C for 3h. 
Immune complexes bound to Protein G Se pharose 
beads were recovered by brief centrifugation and 
washed three times by lysis buffer. Finally, samples 
were boiled in Laemmli sample buffer for 5 min, 
separated by SDS-PAGE and immunoblotted with 
the corresponding antibodies. As a negative control 
we used Protein G Sepharose beads incubated with 
cell lysates and mAbs 2B specifi c to S6K2 isoform. 
Immunofl uorescence analysis – MCF-7 cells cul-
tured on glass slides were fixed with neutrally buff-
ered 10 % formalin (Sigma, USA) for 15 min at 
room temperature. Thereafter, the cells were treated 
with 0.2 % Triton X-100 in PBS (50 μl) for 15 min. 
Then the samples were incubated for 30 min in 50 
mM ammonium acetate (pH 5.0) with 10 mM cupric 
sulphate to eliminate autofl uorescence. Nonspecific 
binding was blocked by the incubation with 10 % 
FCS for 30 min at room temperature. The rabbit pol-
yclonal antibodies (1 μg/ml) were applied in PBS 
(50 μl) at + 4 C in humidifi ed atmosphere overnight. 
(In experiment for deprivation of the CR50 antibod-
ies the synthetic peptide CR50 (10 μg/ml ) was add-
ed to the dilution of the CR50 antibodies prior to 
incubation with the cell samples). The secondary 
FITS-conjugated anti-rabbit antibodies were applied 
in PBS in dilution 1:400 for 1 h at + 30 C (Jackson 
ImmunoResearch, USA). All microscopy studies 
we re performed using Leica DM1000 microscope 
(Leica, Wetzlar, Germany).
Results and Discussion
Since the discovery and molecular cloning of the 
S6K1 gene only two isoforms of the kinase have been 
known for a long time and referred to as p85S6K1 
(525 aa) and p70S6K1(502 aa) (Fig. 1). It is common-
ly accepted that these isoforms originated as a conse-
quence of realization of the alternative mRNA transla-
tional starts [7]. However, recently several splice iso-
forms in mice (S6K1 Iso-2, 316 aa) [11] and human 
(hS6K1-h6A, 209 aa and S6K1-h6C, 219 aa) [12] 
possessing cell transforming properties have been 
identifi ed. 
According to the literature data S6K1 implicated 
in numerous cellular processes, including protein 
synthesis, mRNA processing, glucose homeostasis, 
cell growth and survival targeting about twenty pro-
tein substrates with different subcellular localization 
including the nuclear compartment [1]. It is not clear 
so far, whether p85S6K1, that have exclusively nu-
clear localization according to the immunofl uores-
cence data [8], and the cytoplasmic p70S6K1 form, 
that in fact may shuttle between cytoplasm and nu-
cleus [10] in response to the extracellular stimuli, 
have similar or different functions and whether they 
have the common substrates. Additionally, the im-
munohistochemical analysis of different tumor tis-
sues revealed an increased level of S6K1 in the nu-
clear compartment [13–15] but which of the S6K1 
isoforms is overrepresented is not clear as well. 
 The antibodies specifi c to the 1–23 aa N-terminal 
extension of p85S6K1 that may discriminate the p85 
and p70 kDa isoforms of S6K1 may be very useful 
for such analyses. Earlier it has been claimed the 
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generation of polyclonal antibodies directed to the 
8–23 aa extension of p85S6K1 [8]. However, for so-
me reason the authors excluded the 1–7 aa sequence 
(MRRRRRR) bearing the nuclear localization site 
from the synthetic peptide used for immunization 
that could increase the specifi city of antibodies. 
The aim of this study was to produce the polyclo-
nal antibodies specifi c to the entire N-terminal 1-23 
aa extension of the p85 isoform of S6K1 that differ it 
from a shorter p70 isoform. For this purpose, as an 
antigen for immunization we used the synthetic pep-
tide CR50 (MRRRRRRDGFYPAPDFRHREAED) 
corresponding to the N-terminal extension of p85S6K1 
immobilised on a sepharose carrier. The animal im-
munization was performed according to the regular 
protocol. The titer of anti-p85S6K1 before fi nal 
bleeding was 10-4. The specifi city of affi nity purifi ed 
CR50 polyclonal antibodies has been analysed with 
several tests. According to the data of western blot 
analysis of the MCF7 and HEK293 cell lysates, the 
CR50 polyAbs effi ciently detected a 85 kDa band 
corresponding to the p85 isoform of S6K1 (Fig. 2). 
The specifi city of the p85 isoform recognition by the 
CR50 antibodies was confi rmed by western blot 
analysis of the same cell lysate with the anti-S6K1 
antibodies of other origin (Fig. 2). All antibodies 
used as a referent specifi cally recognised the same 
p85 kDa band. Since these antibodies were generat-
ed to the common for the p85 and p70 isoforms se-
quences (located in the N- or C-terminal regions of 
S6K1), all of them effi ciently recognised the 
p70S6K1 isoform. The C3/10 mAbs were generated 
in our laboratory previously and they are specifi c to 
the C-terminal (454–525 aa) sequence of p85S6K1 
[19]. Commercially available mAbs (clon 16) from 
BD Bioscience are directed to the N-terminal se-
quence (1–122 aa) of p70 S6K1 and the polyclonal 
antibodies a-S6K1/1–77 were generated to the N-te-
rminal (1–77 aa) sequence of p85S6K1 (unpublished 
data). Interestingly, all types of antibodies recog-
nised a unique spectrum of additional minor bands 
that may refl ect some non-specifi c binding of anti-
bodies or recognition of the novel isoforms of S6K1. 
For example mAbs 16 (BD Bioscience) directed to 
the N-terminal region, common for p85 and p70, 
could recognise a 65 kDa band that was not detected 
by the C3/10 mAbs directed to the C-terminal region 
common for both isoforms as well. On the other 
hand, C3/10 could recognise a 60 kDa band that is 
invisible for the mAbs 16. We cannot exclude as well 
that these bands represent proteolytically truncated 
either from N- or C-terminus forms of S6K1. 
Fig. 1. Schematic representation of S6K1 isoforms – p85S6K1 
and p70S6K1 that differs by N-terminal (1–23 aa) extension 
present in p85S6K1 and originated due to realization of alterna-
tive translation start
Fig. 2. Western blot analysis of cell lysates with anti-S6K1 anti-
bodies of different origin: CR50, anti-S6K1 (1-77 aa), 16 (BD 
Bioscience) and C3/10. Cell lysates: 1 – MCF7 (25 μg); 2 – 
HEK293 (25 μg). p85S6K1 and p70S6K1 isoforms are indicated 
by asterisk
Fig. 3. Western blot detection of S6K1 isoforms immunopre-
cipitated from MCF7 cell lysates by anti-S6K1 antibodies (C3/ 
10; CR50; a-S6K1(1–77)) and immunostained with different 
specifi city anti-S6K1 antibodies. MCF7 cell lysate (25 μg)
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For further validation of the CR50 polyAbs spe-
cifi city we performed an immunoprecipitation of 
S6K1 from the cell lysates with a next analysis of the 
immunoprecipitates with different types of the anti-
S6K1 antibodies. According to the data presented in 
Fig. 3 CR50 Abs precipitated p85 S6K1 but did not 
precipitate p70S6K1. As it was expected in western 
blot analysis of C3/10 mAbs immunoprecipitates 
that contain both p70kDa and p85 kDa S6K1 iso-
forms (since they are immunoblotted by C3/10) 
CR50 detected only p85S6K1. Several additional 
bands that were detected by the C3/10 mAbs in 
Fig. 5. Immunofl uorescent localisation of endogenous p85S6K1 in MCF7 cells. Exponentially growing MCF7 cells were cultured 
on coverslips as described Materials and methods) and immunostained with the polyclonal antibodies CR50 (A) and mixture of CR50 
antibodies (B) with immunogenic synthetic peptide corresponding to the N-terminal (1–23 a.a.) extension of p85S6K1.  The localiza-
tion of nuclei in cells is depicted by Hoechst
Fig. 4. Immunofl uorescent localisation of 
endogenous p85S6K1 and p706SK1 in 
MCF7 cells. Exponentially growing MCF7 
cells were cultured on coverslips as des c-
ribed in Materials and methods) and im-
mu nostained with the polyclonal antib-
dies spe cifi c to: C-terminus of S6K1 (an-
ti-S6K1/C) and N-terminal extension of 
p85S6K1 (CR50)
CR50anti-S6K1/C
CR50 Hoechst
HoechstCR50
Merge
Merge
A
B
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CR50 immunoprecipitates (marked by asterisk) may 
refl ect the proteolytical degradation of p85S6K1. 
According to Thomas et al. [8] the antibodies to 
the 8–23 aa sequence of p85S6K1 detected this iso-
form exclusively in the nucleus. According to our 
data the CR50 polyAbs also detected S6K1 predom-
inantly in the nucleus in immunocytochemical anal-
ysis of MCF7 cells in contrast to the anti-S6K1/C 
polyAbs specifi c for both S6K1 isoforms that detect-
ed S6K1 in the cytoplasm and in the nucleus to the 
similar extent (Fig. 4). The specifi city of CR50 anti-
bodies was further confi rmed by the application of 
the synthetic CR50 peptide used as an antigen for 
immunization for the depletion of the CR50 antibod-
ies in immunofl uorescence analysis (Fig. 5). Im-
mu nostaining MCF7 cells by the mixture of CR50 
antibodies and CR50 synthetic peptide completely 
abo lished the nuclear staining. 
As a conclusion, in this study we claim the gen-
eration of polyclonal antibodies specifi c to the N-ter-
minal extension of the p85 isoform of S6K1 that 
could be also present in the recently identifi ed S6K1 
splice isoforms [11, 12] possessing cell transforming 
properties. A high specifi city of the antibodies ana-
lysed in various assays such as western blot, immu-
noprecipitation and immunofl uorescence analysis 
suggests the possibility of their application for the 
evaluation of the S6K1 isoforms functions by analy-
sis of the S6K1 isoforms protein-protein interactions 
(identifi cation of upstream regulators and down-
stream targets), subcellular localization under differ-
ent physiological conditions or at different extracel-
lullar stimuli and alterations of the S6K1 isoforms 
expression and subcellular localisation in the malig-
nant cells of different tumour types. 
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Створення та характеристика поліклональних
 антитіл специфічних до p85 ізоформи кінази
рибосомного білка S6 (p85 S6K1) 
Л. О. Савінська, О. М. Кліпа, А. І. Хоруженко,
К. А. Шкарина, О. М. Гаріфулін, В. В. Філоненко
Мета Отримати поліклональні антитіла специфічні до p85 
ізоформи S6K1 и спрямовані до N-кінцевого (1–23 a.к.) по-
довження p85S6K1 Методи. Іммунизація тварин синтетич-
ним (1–23 а.к.) пептидом, ІФА, вестерн блот, іммунопреци-
пітація, іммуноцитохимічний аналіз. Результати. Отримано 
поліклональні антитіла, що розпізнають p85, але не p70 ізо-
форму S6K1 в вестерн блот анализі, іммунопреципітації і 
іммуноцитохімичному аналізі. Висновки. Отримані анти-
тіла можуть бути рекомендованими для дослідження 
p85S6K1 та інших ізоформ S6K1, що мають N- кінцеве по-
довження – ідентифікації білків-партнерів, аналізу субклі-
тинної локалізації за різних фізіологічних умов, аналізі ролі 
S6K1 ізоформ в сигнальній трансдукції. 
Ключові  слова: кіназа рибосомного білку S6 (S6K1), ізо-
форми S6K1, p70 S6K1, p85 S6K1, поліклональні антитіла.
Получение и характеристика поликлональных
антител специфичных к p85 изоформе киназы
рибосомного белка S6 (p85 S6K1)
Л. А. Савинская, О. Н. Клипа, А. И. Хоруженко,
К. А. Шкарина, О. М. Гарифулин, В. В. Филоненко
Цель. Получить полииклональные антитела специфичные к p85 
изоформе S6K1 и направленные против N-концевого (1–23 a.к.) 
удлинения p85S6K1. Методы. Иммунизация животных синте-
тическим (1–23 а.к.) пептидом, ИФА, вестерн блот, иммуноп-
реципитация, иммуноцитохимический анализ. Результаты. 
Получены поликлональные антитела распознающие p85, но не 
p70 изоформу S6K1 в вестерн блот анализе, иммунопреципита-
ции и иммуноцитохимическом анализе. Выводы. Полученные 
антитела могут быть рекомендованы для изучения p85S6K1 и 
других изоформ S6K1 обладающих N-концевым удлинением – 
идентификации белков партнеров, анализе субклеточной лока-
лизации при разных физиологических условиях, анализе роли 
S6K1 изоформ в сигнальной трансдукции.
Ключевые  слова: киназа рибосомальног белка S6 (S6K1), 
изоформы S6K1, p70 S6K1, p85 S6K1, поликлональные ан-
титела.
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